NASDAQ: MGRXMangoceuticals Inc Stock
$2.49-0.08 (-3.11%)
Updated Apr 21, 2025
MGRX Price
$2.49
Fair Value Price
N/A
Market Cap
$12.87M
52 Week Low
$1.49
52 Week High
$16.80
P/E
-0.51x
P/B
0.92x
P/S
7.78x
PEG
N/A
Dividend Yield
N/A
Revenue
$615.87k
Earnings
-$8.71M
Gross Margin
61.7%
Operating Margin
-1,411.4%
Profit Margin
-1,413.6%
Debt to Equity
0.1
Operating Cash Flow
-$5M
Beta
0.57
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MGRX Overview
Mangoceuticals, Inc. focuses on develops, markets, and sells various men's wellness products and services through a telemedicine platform. It offers erectile dysfunction products under the Mango brand name. The company sells its products through online website mangorx.com. Mangoceuticals, Inc. was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. operates as a subsidiary of Cohen Enterprises, Inc.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MGRX's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Health Information Service
Industry Rating
B
MGRX
Ranked#40 of 44
Ranked#40 of 44
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $145.27 | A | |
| $60.48 | A | |
| $1.36 | B |
Be the first to know about important MGRX news, forecast changes, insider trades & much more!
MGRX News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MGRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MGRX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MGRX is good value based on its book value relative to its share price (0.92x), compared to the US Health Information Services industry average (3.29x)
P/B vs Industry Valuation
MGRX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more MGRX due diligence checks available for Premium users.
Valuation
MGRX fair value
Fair Value of MGRX stock based on Discounted Cash Flow (DCF)
Price
$2.49
Fair Value
-$4.46
Undervalued by
155.81%
MGRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MGRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.51x
Industry
10.54x
Market
27.14x
MGRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.92x
Industry
3.29x
MGRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MGRX's financial health
Profit margin
Revenue
$105.2k
Net Income
-$1.9M
Profit Margin
-1,851.2%
MGRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
MGRX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$15.4M
Liabilities
$1.4M
Debt to equity
0.1
MGRX's short-term liabilities ($1.43M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MGRX's short-term assets ($75.60k) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MGRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.1M
Investing
$0.0
Financing
$1.1M
MGRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MGRX vs Health Information Service Stocks
Mangoceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.